MRNA
Moderna
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
Revenue Plunges
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About MRNA
Moderna, Inc.
A biotech company pioneering messenger RNA (mRNA) therapeutics and vaccines
Biological Technology
07/22/2016
12/07/2018
NASDAQ Stock Exchange
5800
12-31
Common stock
325 Binney Street, Cambridge, Massachusetts 02142
Biopharmaceuticals in genetic engineering
Moderna, Inc., was incorporated under the laws of the State of Delaware on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (messenger ribonucleic acid) medicine. Through more than a decade of work at the intersection of science, technology and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective Covid-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset to responsibly change the future of human health, the company strives to deliver the greatest possible impact to people through mRNA medicines.
Company Financials
EPS
MRNA has released its 2024 Q4 earnings. EPS was reported at -2.91, versus the expected -2.76, missing expectations. The chart below visualizes how MRNA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MRNA has released its 2024 Q4 earnings report, with revenue of 966.00M, reflecting a YoY change of -65.64%, and net profit of -1.12B, showing a YoY change of -616.13%. The Sankey diagram below clearly presents MRNA’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
